Calcitonin gene-related peptide: a possible biomarker in migraine patients with patent foramen ovale
This study aimed to investigate the differential expression of calci... (Source: BMC Neurology)
Source: BMC Neurology - April 16, 2024 Category: Neurology Authors: Chaojie Li, Yu Yu, Ningning Li, Ya-Na Yin, Lianjun Zhang, Kehang Xie and Donghui Huang Tags: Research Source Type: research
Alteration in the expression of long non-coding RNAs in the circulation of migraineurs
ConclusionCumulatively, our study shows evidence for deregulation of lncRNAs in migraineurs. (Source: Acta Neurologica Belgica)
Source: Acta Neurologica Belgica - April 16, 2024 Category: Neurology Source Type: research
Acute Treatment Patterns, Migraine Burden, and Healthcare Resource Use in People With Migraine: Results From the OVERCOME (EU) Observational Study
ConclusionHigh migraine-related burden levels were reported, despite use of acute medication. Although triptans are recommended for moderate to severe migraine attacks in Spanish and German guidelines, less than half of participants were using triptans; treatment satisfaction in those using triptans was generally poor. New tailored treatment options may help address unmet needs in current acute treatment. (Source: Pain and Therapy)
Source: Pain and Therapy - April 16, 2024 Category: Anesthesiology Source Type: research
Efficacy and safety of antibiotics for treatment of leptospirosis: a systematic review and network meta-analysis
ConclusionsFindings recommend that leptospirosis patients be treated with antibiotics, which significantly reduced the leptospirosis defervescence time. Cephalosporins, doxycycline, and penicillin are suggested, and azithromycin may be a suitable alternative for drug-resistant cases.Systematic review registrationPROSPERO CRD42022354938. (Source: Systematic Reviews)
Source: Systematic Reviews - April 16, 2024 Category: International Medicine & Public Health Source Type: research
Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study
ConclusionTCZ can treat active moderate-to-severe TED, showing high drug compliance and reasonable response to inflammation and extraocular motility abnormality. (Source: International Ophthalmology)
Source: International Ophthalmology - April 16, 2024 Category: Opthalmology Source Type: research
Non-targeted serial epidural blood patching for the treatment of intracranial hypotension headache during late pregnancy: a case report
Intracranial hypotension can cause debilitating headaches, commonly due to the leakage of cerebrospinal fluid (CSF) through a spinal dural defect or a CSF-venous fistula.1 It can also occur spontaneously, at an estimated annual rate of 5 per 100 000.2 Although the most common presentation is orthostatic headaches,3 the symptoms can be non-specific and include nausea, neck stiffness, blurred vision, and various neurological deficits,1,4 sharing similarities with those of migraine.5 Therefore, the diagnosis of intracranial hypotension can be challenging and is often missed or delayed. (Source: International Journal of Obstetric Anesthesia)
Source: International Journal of Obstetric Anesthesia - April 16, 2024 Category: Anesthesiology Authors: O. Onuoha, K. Brown, Y. Jiang, B. Orlando Tags: Case Report Source Type: research
Rimegepant orally disintegrating tablet 75 mg for acute treatment of migraine in adults from China: a subgroup analysis of a double-blind, randomized, placebo-controlled, phase 3 clinical trial
ConclusionsA single dose of rimegepant 75 mg rimegepant was effective for the acute treatment of migraine in adults living in China, with safety and tolerability similar to placebo.Trial registration Clinicaltrials.gov NCT04574362 Date registered: 2020-10-05.Graphical Abstract (Source: The Journal of Headache and Pain)
Source: The Journal of Headache and Pain - April 16, 2024 Category: Neurology Source Type: research
COVID-19 presenting with nystagmus
Arch Soc Esp Oftalmol. 2021 Apr;96(4):224-226. doi: 10.1016/j.oftal.2020.09.008. Epub 2020 Nov 6.ABSTRACTThis case reports a 20-year-old female patient who was in northern Italy when the state of emergency was declared on the 31st of January 2020, developing 15 days after return to Spain upper respiratory symptoms characterized by fever, headache and anosmia that was treated as sinusitis. Three weeks later presented with dizziness and an intermittent horizontal nystagmus with rotatory component. Otorhinolaryngology and neurological examination including MRI were normal. COVID-19 IgG antibodies where positive. In the contex...
Source: Archivos de la Sociedad Espanola de Oftalmologia - April 15, 2024 Category: Opthalmology Authors: E Garc ía-Romo R Blanco C Nicholls A Hern ández-Tejero B Fern ández-de-Arévalo Source Type: research
Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease
CONCLUSIONS: Daprodustat is a novel oral, non-iron therapy for treatment of anemia of CKD. It was Food and Drug Administration approved in 2023 in patients already receiving dialysis for at least 4 months but not in non-dialysis patients. Long-term data for safety and additional benefits are pending.PMID:38616529 | DOI:10.1177/10600280241241563 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 15, 2024 Category: Drugs & Pharmacology Authors: Haley N Johnson Lalita Prasad-Reddy Source Type: research
COVID-19 presenting with nystagmus
Arch Soc Esp Oftalmol. 2021 Apr;96(4):224-226. doi: 10.1016/j.oftal.2020.09.008. Epub 2020 Nov 6.ABSTRACTThis case reports a 20-year-old female patient who was in northern Italy when the state of emergency was declared on the 31st of January 2020, developing 15 days after return to Spain upper respiratory symptoms characterized by fever, headache and anosmia that was treated as sinusitis. Three weeks later presented with dizziness and an intermittent horizontal nystagmus with rotatory component. Otorhinolaryngology and neurological examination including MRI were normal. COVID-19 IgG antibodies where positive. In the contex...
Source: Archivos de la Sociedad Espanola de Oftalmologia - April 15, 2024 Category: Opthalmology Authors: E Garc ía-Romo R Blanco C Nicholls A Hern ández-Tejero B Fern ández-de-Arévalo Source Type: research
Daprodustat: A Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor for Anemia of Chronic Kidney Disease
CONCLUSIONS: Daprodustat is a novel oral, non-iron therapy for treatment of anemia of CKD. It was Food and Drug Administration approved in 2023 in patients already receiving dialysis for at least 4 months but not in non-dialysis patients. Long-term data for safety and additional benefits are pending.PMID:38616529 | DOI:10.1177/10600280241241563 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - April 15, 2024 Category: Drugs & Pharmacology Authors: Haley N Johnson Lalita Prasad-Reddy Source Type: research
